CCR2 and prostate carcinoma: A different strategy of macrophage polarization targets the C-C motif chemokine ligand 2 (CCL2)/C-C motif chemokine receptor 2 (CCR2) axis with available drugs such as carlumab, which was well tolerated but not effective in a phase 2 trial of efficacy in metastatic castration-resistant prostate cancer [57].